Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study

Recomendaciones preventivas cardiovasculares

(2013) Antonio Maiques Galán et al.   Atencion Primaria

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins

(2013) Ferrán Catalá-López et al.   PLoS One

Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

(2013) C. R. Dormuth et al.   BMJ-British Medical Journal

Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

(2013) Huseyin Naci et al.   European Journal of Preventive Cardiology

Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy

(2012) Matthew K Ito   ANNALS OF PHARMACOTHERAPY

Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case–control study in a new general practice database

(2012) Francisco J. de Abajo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Lipid-Modifying Therapies and Risk of Pancreatitis

(2012) David Preiss et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Effect of Thyroid Disorders on Lipid Levels and Metabolism

(2012) Leonidas H. Duntas et al.   MEDICAL CLINICS OF NORTH AMERICA

Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use in an Insured US Population

(2011) Kandace L Amend et al.   ANNALS OF PHARMACOTHERAPY

Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era

(2011) Lawrence D. Lazar et al.   CIRCULATION

Initiation of Statin Therapy: Are There Age Limits?

(2011) Dipan A. Desai et al.   Current Atherosclerosis Reports

Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia

(2010) Michael S. Kostapanos et al.   American Journal of Cardiovascular Drugs

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

(2010) Paul M Ridker et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

(2010)   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE